首页 > 最新文献

IJU Case Reports最新文献

英文 中文
A case of rapidly progressive prostate cancer with bone and lymph node metastasis after contact laser vaporization for benign prostatic hyperplasia 接触性激光汽化治疗良性前列腺增生后迅速进展的前列腺癌伴骨及淋巴结转移1例。
Q4 Medicine Pub Date : 2024-10-25 DOI: 10.1002/iju5.12806
Kei Muraoka, Akira Fujisaki, Kosuke Uchida, Yasuhiro Hakamata, Yuka Kanda, Kota Sugiura, Masashi Yoshida, Shin Imai, Yoshiro Otsuki, Tatsuaki Yoneda

Introduction

Prostate cancer is incidentally diagnosed in 6%–11% of benign prostatic hyperplasia surgeries.

Case presentation

A 79-year-old man was diagnosed with benign prostatic hyperplasia. The prostate volume was 54.5 mL, and the prostate-specific antigen level was 7.121 ng/mL. Magnetic resonance imaging and prostate biopsy were not performed. He then underwent contact laser vaporization of the prostate. After 3 months, gross hematuria occurred, and the prostate-specific antigen level was 62.495 ng/mL. Cystoscopy and magnetic resonance imaging revealed prostate cancer with bladder invasion. Prostate biopsy and transurethral resection were performed, revealing adenocarcinoma with a Gleason score of 5 + 5. The patient was diagnosed with prostate cancer T4N1M1b, and triplet therapy was initiated. After 6 months, the prostate-specific antigen level was 0.037 ng/mL, and the metastases had shrunk.

Conclusion

Vaporization for high-grade prostate cancer can lead to rapid progression. Therefore, screening for prostate cancer before benign prostatic hyperplasia surgery is important.

前列腺癌在6%-11%的良性前列腺增生手术中被偶然诊断。病例介绍:一名79岁男性被诊断为良性前列腺增生。前列腺体积54.5 mL,前列腺特异性抗原水平7.121 ng/mL。未行磁共振成像和前列腺活检。然后他接受了前列腺接触激光汽化。3个月后出现肉眼血尿,前列腺特异性抗原62.495 ng/mL。膀胱镜及核磁共振显示前列腺癌伴膀胱浸润。行前列腺活检和经尿道切除术,显示腺癌,Gleason评分为5 + 5。患者被诊断为前列腺癌T4N1M1b,并开始三联治疗。6个月后,前列腺特异性抗原水平为0.037 ng/mL,转移灶缩小。结论:汽化治疗高级别前列腺癌进展迅速。因此,在前列腺增生手术前进行前列腺癌筛查是很重要的。
{"title":"A case of rapidly progressive prostate cancer with bone and lymph node metastasis after contact laser vaporization for benign prostatic hyperplasia","authors":"Kei Muraoka,&nbsp;Akira Fujisaki,&nbsp;Kosuke Uchida,&nbsp;Yasuhiro Hakamata,&nbsp;Yuka Kanda,&nbsp;Kota Sugiura,&nbsp;Masashi Yoshida,&nbsp;Shin Imai,&nbsp;Yoshiro Otsuki,&nbsp;Tatsuaki Yoneda","doi":"10.1002/iju5.12806","DOIUrl":"10.1002/iju5.12806","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Prostate cancer is incidentally diagnosed in 6%–11% of benign prostatic hyperplasia surgeries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A 79-year-old man was diagnosed with benign prostatic hyperplasia. The prostate volume was 54.5 mL, and the prostate-specific antigen level was 7.121 ng/mL. Magnetic resonance imaging and prostate biopsy were not performed. He then underwent contact laser vaporization of the prostate. After 3 months, gross hematuria occurred, and the prostate-specific antigen level was 62.495 ng/mL. Cystoscopy and magnetic resonance imaging revealed prostate cancer with bladder invasion. Prostate biopsy and transurethral resection were performed, revealing adenocarcinoma with a Gleason score of 5 + 5. The patient was diagnosed with prostate cancer T4N1M1b, and triplet therapy was initiated. After 6 months, the prostate-specific antigen level was 0.037 ng/mL, and the metastases had shrunk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vaporization for high-grade prostate cancer can lead to rapid progression. Therefore, screening for prostate cancer before benign prostatic hyperplasia surgery is important.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"47-51"},"PeriodicalIF":0.0,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initial experience of 980-nm diode laser treatment for recurrent non-muscle-invasive bladder cancer 980纳米二极管激光治疗复发性非肌浸润性膀胱癌的初步体会。
Q4 Medicine Pub Date : 2024-10-25 DOI: 10.1002/iju5.12803
Hideo Fukuhara, Yusei Hamada, Syo Shimasaki, Ryohei Iga, Kaya Atagi, Ryu Shigehisa, Yuhi Ota, Shinkuro Yamamoto, Hiroto Osakabe, Tomoya Nao, Tsutomu Shimamoto, Satosi Fukata, Shingo Ashida, Takashi Karashima, Keiji Inoue

Introduction

Laser ablation using a 980-nm wavelength diode laser, which is a new-generation laser, for recurrent bladder cancer is known to have a lower incidence of complications and recurrence than conventional transurethral resection of bladder tumor surgery. This is the first study to report the use of 980-nm diode laser ablation for recurrent non-muscle-invasive bladder cancer in Japan.

Case presentation

A 73-year-old man underwent transurethral laser ablation for the treatment of recurrent non-muscle-invasive bladder cancer. Laser irradiation was performed using LEONARDO DUAL (diode laser/980-nm wavelength) and a 400-μm BARE laser fiber. Pathological evaluation indicated low-grade urothelial carcinoma, pTa. The patient was discharged on the second postoperative day with no perioperative or postoperative complications.

Conclusion

This case suggests the potential of transurethral laser ablation for treating recurrent non-muscle-invasive bladder cancer.

简介:980 nm波长二极管激光是新一代激光,用于复发性膀胱癌的激光消融比传统经尿道膀胱肿瘤切除术具有更低的并发症发生率和复发率。这是日本首次报道使用980纳米二极管激光消融治疗复发性非肌肉浸润性膀胱癌。病例介绍:一名73岁男性接受经尿道激光消融治疗复发性非肌肉侵袭性膀胱癌。激光照射采用LEONARDO DUAL(二极管激光器/980 nm波长)和400 μm BARE激光光纤。病理诊断为低级别尿路上皮癌,pTa。患者于术后第二天出院,无围手术期及术后并发症。结论:本病例提示经尿道激光消融治疗复发性非肌浸润性膀胱癌的潜力。
{"title":"Initial experience of 980-nm diode laser treatment for recurrent non-muscle-invasive bladder cancer","authors":"Hideo Fukuhara,&nbsp;Yusei Hamada,&nbsp;Syo Shimasaki,&nbsp;Ryohei Iga,&nbsp;Kaya Atagi,&nbsp;Ryu Shigehisa,&nbsp;Yuhi Ota,&nbsp;Shinkuro Yamamoto,&nbsp;Hiroto Osakabe,&nbsp;Tomoya Nao,&nbsp;Tsutomu Shimamoto,&nbsp;Satosi Fukata,&nbsp;Shingo Ashida,&nbsp;Takashi Karashima,&nbsp;Keiji Inoue","doi":"10.1002/iju5.12803","DOIUrl":"10.1002/iju5.12803","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Laser ablation using a 980-nm wavelength diode laser, which is a new-generation laser, for recurrent bladder cancer is known to have a lower incidence of complications and recurrence than conventional transurethral resection of bladder tumor surgery. This is the first study to report the use of 980-nm diode laser ablation for recurrent non-muscle-invasive bladder cancer in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A 73-year-old man underwent transurethral laser ablation for the treatment of recurrent non-muscle-invasive bladder cancer. Laser irradiation was performed using LEONARDO DUAL (diode laser/980-nm wavelength) and a 400-μm BARE laser fiber. Pathological evaluation indicated low-grade urothelial carcinoma, pTa. The patient was discharged on the second postoperative day with no perioperative or postoperative complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case suggests the potential of transurethral laser ablation for treating recurrent non-muscle-invasive bladder cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"41-43"},"PeriodicalIF":0.0,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound-guided embolization for renal artery pseudoaneurysm in solitary kidney 超声引导下栓塞治疗单肾肾动脉假性动脉瘤。
Q4 Medicine Pub Date : 2024-10-22 DOI: 10.1002/iju5.12796
Sana Augustine, Mitwa Patel, Pugazhendi Inban, Sk Sadia Rahman Synthia, Ummul Z Asfeen, Aliza Yaqub, Aadil Mahmood Khan, Mansi Singh

Introduction

Renal artery pseudoaneurysm is a rare yet serious complication following percutaneous nephrolithotomy, especially in patients with solitary kidneys. Effective management is crucial to prevent further renal damage.

Case presentation

We report a case of a 41-year-old male with a solitary kidney who experienced gross hematuria and renal insufficiency 3 months after percutaneous nephrolithotomy. Due to the patient's renal insufficiency and the risks associated with arterial catheterization, ultrasound-guided embolization was chosen as the treatment approach. Initial angiographic attempts were impeded by renal vessel spasms, delaying intervention. However, successful direct percutaneous embolization was subsequently performed using ultrasound and digital subtraction angiography.

Conclusion

The patient's recovery was uneventful, and follow-up assessments showed no recurrence of renal artery pseudoaneurysm. This case highlights the effectiveness of ultrasound-guided embolization as a viable treatment option for post-percutaneous nephrolithotomy renal artery pseudoaneurysm, particularly in patients with solitary kidneys.

摘要肾动脉假性动脉瘤是经皮肾镜取石术后罕见但严重的并发症,尤其在孤立肾患者中。有效的治疗是防止进一步肾脏损害的关键。病例介绍:我们报告一例41岁男性单肾患者,经皮肾镜取石术3个月后出现明显血尿和肾功能不全。考虑到患者肾功能不全及动脉置管的风险,我们选择超声引导下栓塞治疗。最初的血管造影尝试因肾血管痉挛而受阻,延迟了干预。然而,随后使用超声和数字减影血管造影进行了成功的直接经皮栓塞。结论:患者康复顺利,随访无肾动脉假性动脉瘤复发。本病例强调了超声引导下栓塞作为经皮肾镜取石术后肾动脉假性动脉瘤的可行治疗选择的有效性,特别是在孤立肾患者中。
{"title":"Ultrasound-guided embolization for renal artery pseudoaneurysm in solitary kidney","authors":"Sana Augustine,&nbsp;Mitwa Patel,&nbsp;Pugazhendi Inban,&nbsp;Sk Sadia Rahman Synthia,&nbsp;Ummul Z Asfeen,&nbsp;Aliza Yaqub,&nbsp;Aadil Mahmood Khan,&nbsp;Mansi Singh","doi":"10.1002/iju5.12796","DOIUrl":"10.1002/iju5.12796","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Renal artery pseudoaneurysm is a rare yet serious complication following percutaneous nephrolithotomy, especially in patients with solitary kidneys. Effective management is crucial to prevent further renal damage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>We report a case of a 41-year-old male with a solitary kidney who experienced gross hematuria and renal insufficiency 3 months after percutaneous nephrolithotomy. Due to the patient's renal insufficiency and the risks associated with arterial catheterization, ultrasound-guided embolization was chosen as the treatment approach. Initial angiographic attempts were impeded by renal vessel spasms, delaying intervention. However, successful direct percutaneous embolization was subsequently performed using ultrasound and digital subtraction angiography.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The patient's recovery was uneventful, and follow-up assessments showed no recurrence of renal artery pseudoaneurysm. This case highlights the effectiveness of ultrasound-guided embolization as a viable treatment option for post-percutaneous nephrolithotomy renal artery pseudoaneurysm, particularly in patients with solitary kidneys.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"19-23"},"PeriodicalIF":0.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vogt-Koyanagi-Harada disease-like uveitis induced by nivolumab in metastatic renal cell carcinoma 转移性肾细胞癌中的 nivolumab 引起的 Vogt-Koyanagi-Harada 病样葡萄膜炎
Q4 Medicine Pub Date : 2024-10-21 DOI: 10.1002/iju5.12801
Hitomi Imai, Tomoyuki Koguchi, Yuki Harigane, Kei Yaginuma, Satoru Meguro, Seiji Hoshi, Junya Hata, Hidenori Akaihata, Soichiro Ogawa, Yoshiyuki Kojima

Introduction

Nivolumab can cause various immune-related adverse events; it rarely induces Vogt-Koyanagi-Harada-disease-like uveitis. Vogt-Koyanagi-Harada-disease is reported to be closely associated with human leukocyte antigen-DR4.

Case presentation

A 68-year-old man with metastatic renal cancer underwent nephrectomy. Computed tomography showed multiple lung tumors, raising suspicion of lung metastases. However, one lung hilar mass was suspected to be primary lung cancer, leading to a lobectomy, which subsequently revealed lung metastases of renal cancer. The patient underwent nivolumab treatment but developed Vogt-Koyanagi-Harada-disease-like uveitis as an immune-related adverse event. Human leukocyte antigen-DR4 alleles were identified, and the uveitis improved with topical steroids. He maintained partial response of lung metastases after nivolumab resumption. Immunohistochemical staining revealed significantly higher human leukocyte antigen-DR4 expression in lung metastasis than primary renal cancer.

Conclusion

Despite inducing Vogt-Koyanagi-Harada-disease-like uveitis, nivolumab controlled cancer progression effectively. Immunohistochemical staining results suggest the potential involvement of human leukocyte antigen-DR4 expression in both the onset of Vogt-Koyanagi-Harada-disease-like uveitis and nivolumab efficacy.

Nivolumab可引起各种免疫相关不良事件;它很少引起类似vogt - koyanagi - harada病的葡萄膜炎。据报道,vogt - koyanagi - harada病与人类白细胞抗原dr4密切相关。病例介绍:一名68岁男性转移性肾癌行肾切除术。计算机断层扫描显示多发肺肿瘤,怀疑有肺转移。然而,一个肺门肿块被怀疑是原发性肺癌,导致肺叶切除术,随后发现肺转移的肾癌。患者接受了纳武单抗治疗,但出现了vogt - koyanagi - harada病样葡萄膜炎作为免疫相关不良事件。发现了人白细胞抗原dr4等位基因,局部类固醇治疗后葡萄膜炎得到改善。在纳武单抗恢复后,他保持了肺转移的部分缓解。免疫组化染色显示人白细胞抗原dr4在肺转移癌中的表达明显高于原发性肾癌。结论:尽管会诱导vogt - koyanagi - harada病样葡萄膜炎,但nivolumab可有效控制癌症进展。免疫组织化学染色结果提示,人白细胞抗原dr4表达可能参与vogt - koyanagi - harada病样葡萄膜炎的发病和纳武单抗的疗效。
{"title":"Vogt-Koyanagi-Harada disease-like uveitis induced by nivolumab in metastatic renal cell carcinoma","authors":"Hitomi Imai,&nbsp;Tomoyuki Koguchi,&nbsp;Yuki Harigane,&nbsp;Kei Yaginuma,&nbsp;Satoru Meguro,&nbsp;Seiji Hoshi,&nbsp;Junya Hata,&nbsp;Hidenori Akaihata,&nbsp;Soichiro Ogawa,&nbsp;Yoshiyuki Kojima","doi":"10.1002/iju5.12801","DOIUrl":"10.1002/iju5.12801","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Nivolumab can cause various immune-related adverse events; it rarely induces Vogt-Koyanagi-Harada-disease-like uveitis. Vogt-Koyanagi-Harada-disease is reported to be closely associated with human leukocyte antigen-DR4.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A 68-year-old man with metastatic renal cancer underwent nephrectomy. Computed tomography showed multiple lung tumors, raising suspicion of lung metastases. However, one lung hilar mass was suspected to be primary lung cancer, leading to a lobectomy, which subsequently revealed lung metastases of renal cancer. The patient underwent nivolumab treatment but developed Vogt-Koyanagi-Harada-disease-like uveitis as an immune-related adverse event. Human leukocyte antigen-DR4 alleles were identified, and the uveitis improved with topical steroids. He maintained partial response of lung metastases after nivolumab resumption. Immunohistochemical staining revealed significantly higher human leukocyte antigen-DR4 expression in lung metastasis than primary renal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Despite inducing Vogt-Koyanagi-Harada-disease-like uveitis, nivolumab controlled cancer progression effectively. Immunohistochemical staining results suggest the potential involvement of human leukocyte antigen-DR4 expression in both the onset of Vogt-Koyanagi-Harada-disease-like uveitis and nivolumab efficacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"36-40"},"PeriodicalIF":0.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robot-assisted radical cystectomy using real-time transrectal ultrasound guidance in a patient who had radical prostatectomy and salvage external beam radiation therapy 实时经直肠超声引导下的机器人辅助根治性膀胱切除术在根治性前列腺切除术和挽救外束放射治疗中的应用。
Q4 Medicine Pub Date : 2024-10-14 DOI: 10.1002/iju5.12799
Yuta Inoue, Takeshi Yamada, Yuji Okusa, Hideto Taga, Takashi Ueda, Takumi Shiraishi, Atsuko Fujihara, Masayoshi Okumi, Fumiya Hongo, Osamu Ukimura

Introduction

Radical cystectomy for patients who previously underwent both radical prostatectomy and prostatic bed radiation is technically challenging.

Case presentation

A 78-year-old man with a history of radical prostatectomy and salvage radiation for prostate cancer was referred to our hospital for radical treatment of bladder cancer. After two cycles of neoadjuvant chemotherapy, he underwent robot-assisted radical cystectomy with real-time transrectal ultrasound guidance during dissection of the rectovesical space to minimize the risk of rectal injury. There were no perioperative adverse events.

Conclusion

Intraoperative real-time transrectal ultrasound guidance could assist surgeons to safely perform the dissection of the rectovesical space in the surgically high-risk patient.

导读:根治性膀胱切除术对于曾接受根治性前列腺切除术和前列腺床放射治疗的患者在技术上具有挑战性。病例介绍:一名78岁男性患者因前列腺癌行根治性前列腺切除术和补救性放射治疗而来我院接受膀胱癌根治性治疗。在两个周期的新辅助化疗后,他在解剖直肠膀胱间隙的同时,在实时经直肠超声引导下进行了机器人辅助根治性膀胱切除术,以减少直肠损伤的风险。无围手术期不良事件发生。结论:术中实时经直肠超声引导可帮助外科高危患者安全进行直肠膀胱间隙清扫。
{"title":"Robot-assisted radical cystectomy using real-time transrectal ultrasound guidance in a patient who had radical prostatectomy and salvage external beam radiation therapy","authors":"Yuta Inoue,&nbsp;Takeshi Yamada,&nbsp;Yuji Okusa,&nbsp;Hideto Taga,&nbsp;Takashi Ueda,&nbsp;Takumi Shiraishi,&nbsp;Atsuko Fujihara,&nbsp;Masayoshi Okumi,&nbsp;Fumiya Hongo,&nbsp;Osamu Ukimura","doi":"10.1002/iju5.12799","DOIUrl":"10.1002/iju5.12799","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Radical cystectomy for patients who previously underwent both radical prostatectomy and prostatic bed radiation is technically challenging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A 78-year-old man with a history of radical prostatectomy and salvage radiation for prostate cancer was referred to our hospital for radical treatment of bladder cancer. After two cycles of neoadjuvant chemotherapy, he underwent robot-assisted radical cystectomy with real-time transrectal ultrasound guidance during dissection of the rectovesical space to minimize the risk of rectal injury. There were no perioperative adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Intraoperative real-time transrectal ultrasound guidance could assist surgeons to safely perform the dissection of the rectovesical space in the surgically high-risk patient.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"28-31"},"PeriodicalIF":0.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enteritis of the ileal conduit as an adverse event related to immune checkpoint inhibitor use 回肠导管肠炎作为免疫检查点抑制剂使用相关的不良事件。
Q4 Medicine Pub Date : 2024-10-14 DOI: 10.1002/iju5.12797
Ko Kobayashi, Kohei Hashimoto, Toshiaki Tanaka, Naoya Masumori

Introduction

Gastroenterocolitis is one of the adverse events related to immune checkpoint inhibitors. However, inflammation of the intestinal lesion used for urinary diversion is not well known as an adverse event related to their use.

Case presentation

A patient with metastatic bladder cancer was administered pembrolizumab as second-line treatment. After 12 days of administration, he felt abdominal distention. Computed tomography demonstrated thickening of the ileal conduit wall and bilateral hydronephrosis. Biopsy of the ileal conduit revealed inflammatory granulation tissue. Biopsy of the sigmoid colon also revealed colitis. Therefore, we diagnosed enterocolitis including the ileal conduit related to pembrolizumab. We then started to administer 30 mg prednisolone. After this treatment, we confirmed improvement of the clinical symptoms and healing of the ileal conduit mucosa.

Conclusion

Inflammation of an ileal conduit can occur as an immune-related adverse event caused by metastatic urothelial carcinoma treatment with pembrolizumab.

胃肠结肠炎是与免疫检查点抑制剂相关的不良事件之一。然而,用于尿转移的肠道病变炎症并不是众所周知的与它们的使用相关的不良事件。病例介绍:转移性膀胱癌患者给予派姆单抗作为二线治疗。服药12天后,他感到腹胀。计算机断层扫描显示回肠导管壁增厚和双侧肾积水。回肠导管活检显示炎性肉芽组织。乙状结肠活检也显示结肠炎。因此,我们诊断出与派姆单抗相关的肠结肠炎包括回肠导管。​经此治疗后,我们证实临床症状改善,回肠导管粘膜愈合。结论:使用派姆单抗治疗转移性尿路上皮癌时,回肠导管炎症可作为免疫相关不良事件发生。
{"title":"Enteritis of the ileal conduit as an adverse event related to immune checkpoint inhibitor use","authors":"Ko Kobayashi,&nbsp;Kohei Hashimoto,&nbsp;Toshiaki Tanaka,&nbsp;Naoya Masumori","doi":"10.1002/iju5.12797","DOIUrl":"10.1002/iju5.12797","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Gastroenterocolitis is one of the adverse events related to immune checkpoint inhibitors. However, inflammation of the intestinal lesion used for urinary diversion is not well known as an adverse event related to their use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A patient with metastatic bladder cancer was administered pembrolizumab as second-line treatment. After 12 days of administration, he felt abdominal distention. Computed tomography demonstrated thickening of the ileal conduit wall and bilateral hydronephrosis. Biopsy of the ileal conduit revealed inflammatory granulation tissue. Biopsy of the sigmoid colon also revealed colitis. Therefore, we diagnosed enterocolitis including the ileal conduit related to pembrolizumab. We then started to administer 30 mg prednisolone. After this treatment, we confirmed improvement of the clinical symptoms and healing of the ileal conduit mucosa.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Inflammation of an ileal conduit can occur as an immune-related adverse event caused by metastatic urothelial carcinoma treatment with pembrolizumab.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"24-27"},"PeriodicalIF":0.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tips for percutaneous nephrolithotomy for transplant kidney stone 经皮肾镜取石术治疗移植肾结石的注意事项。
Q4 Medicine Pub Date : 2024-10-13 DOI: 10.1002/iju5.12800
Takafumi Yagisawa, Tomokazu Shimizu, Ayane Tachiki, Yudai Ishiyama, Tadashi Onohara, Shoichi Iida, Hideki Ishida, Toshio Takagi

Introduction

The management of urinary tract stones, particularly de novo kidney allograft stones, presents unique challenges for kidney transplant recipients because of their prevalence and specific clinical considerations. Here, we describe a case in which percutaneous nephrolithotomy was successfully used to fragment a large kidney allograft stone ≥20 mm in size.

Case presentation

A 57-year-old woman who underwent ureteroureterostomy post simultaneous pancreas–kidney transplantation presented with gross hematuria after 15 years. Computed tomography revealed a 23-mm stone in the transplanted kidney. Initial attempts at endoscopic combined intrarenal surgery were changed to percutaneous nephrolithotomy because of poor ureter mobility and tortuosity. Stone fragmentation was achieved using pneumatic and ultrasonic lithotripsy. A second procedure using Swiss LithoClast® Trilogy enabled complete stone clearance and ureteral stent placement.

Conclusion

By understanding the peculiarities of the percutaneous approach, we demonstrated the safe and effective use of a pneumatic and ultrasonic lithotripter for kidney allograft stone fragmentation.

导言:尿路结石的治疗,特别是新生肾移植结石,由于其普遍性和特殊的临床考虑,对肾移植受者提出了独特的挑战。在这里,我们描述了一个病例,经皮肾镜取石术成功地粉碎了一个大小≥20毫米的大的同种异体肾移植结石。病例介绍:一名57岁女性,在胰肾联合移植术后行输尿管输尿管造口术,15年后出现肉眼血尿。计算机断层扫描显示移植肾中有一块23毫米的结石。最初尝试的内镜联合肾内手术改为经皮肾镜取石术,因为输尿管流动性差和弯曲。采用气动和超声波碎石实现了碎石的破碎。第二次手术采用瑞士LithoClast®Trilogy,可以完全清除结石并放置输尿管支架。结论:通过了解经皮入路的特点,我们证明了气动和超声碎石机用于同种异体肾移植结石碎裂的安全有效。
{"title":"Tips for percutaneous nephrolithotomy for transplant kidney stone","authors":"Takafumi Yagisawa,&nbsp;Tomokazu Shimizu,&nbsp;Ayane Tachiki,&nbsp;Yudai Ishiyama,&nbsp;Tadashi Onohara,&nbsp;Shoichi Iida,&nbsp;Hideki Ishida,&nbsp;Toshio Takagi","doi":"10.1002/iju5.12800","DOIUrl":"10.1002/iju5.12800","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The management of urinary tract stones, particularly <i>de novo</i> kidney allograft stones, presents unique challenges for kidney transplant recipients because of their prevalence and specific clinical considerations. Here, we describe a case in which percutaneous nephrolithotomy was successfully used to fragment a large kidney allograft stone ≥20 mm in size.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A 57-year-old woman who underwent ureteroureterostomy post simultaneous pancreas–kidney transplantation presented with gross hematuria after 15 years. Computed tomography revealed a 23-mm stone in the transplanted kidney. Initial attempts at endoscopic combined intrarenal surgery were changed to percutaneous nephrolithotomy because of poor ureter mobility and tortuosity. Stone fragmentation was achieved using pneumatic and ultrasonic lithotripsy. A second procedure using Swiss LithoClast<sup>®</sup> Trilogy enabled complete stone clearance and ureteral stent placement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>By understanding the peculiarities of the percutaneous approach, we demonstrated the safe and effective use of a pneumatic and ultrasonic lithotripter for kidney allograft stone fragmentation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"32-35"},"PeriodicalIF":0.0,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare huge bilateral adrenal myelolipoma confused with retroperitoneal liposarcoma 罕见的巨大双侧肾上腺骨髓瘤与腹膜后脂肪肉瘤混淆。
Q4 Medicine Pub Date : 2024-10-11 DOI: 10.1002/iju5.12792
Kana Ito, Ryo Yamashita, Yuma Sakura, Hideo Shinsaka, Masafumi Nakamura, Masato Matsuzaki, Masashi Niwakawa, Tsubasa Hiraki

Introduction

Adrenal myelolipomas are uncommon benign adrenal tumors, which mostly occur unilaterally. We describe a rare case of giant bilateral adrenal myelolipoma mistaken for retroperitoneal liposarcoma.

Case presentation

A 49-year-old man developed fever, left flank pain, and a large mass in his left abdomen. Plain computed tomography showed a 23-cm mass with fat-containing components in the retroperitoneal cavity, suggestive of retroperitoneal liposarcoma. A similar 9-cm mass was observed in the right adrenal gland, suggesting adrenal metastasis. With a clinical diagnosis of retroperitoneal liposarcoma, we administered preoperative radiation therapy and performed a bilateral tumor resection. On postoperative day 9, a surgical site infection occurred, necessitating incisional drainage and the administration of intravenous antibiotics. The histopathological diagnosis was bilateral myelolipoma of the adrenal glands.

Conclusion

In cases of bilateral retroperitoneal tumors with a large fat component, adrenal myelolipoma should be considered in the differential diagnosis to avoid overtreatment.

简介:肾上腺骨髓脂肪瘤是少见的肾上腺良性肿瘤,多发生于单侧。我们报告一例罕见的双侧巨大肾上腺骨髓瘤误诊为腹膜后脂肪肉瘤的病例。病例介绍:一名49岁男性,出现发热、左侧腰痛及左腹部大肿块。ct平扫显示腹膜后腔有一个23厘米的肿块,含脂肪成分,提示腹膜后脂肪肉瘤。右侧肾上腺也有类似的9厘米肿块,提示肾上腺转移。临床诊断为腹膜后脂肪肉瘤,我们给予术前放疗并行双侧肿瘤切除术。术后第9天,发生手术部位感染,需要切口引流和静脉注射抗生素。病理诊断为双侧肾上腺骨髓瘤。结论:双侧腹膜后肿瘤脂肪成分大时,应考虑肾上腺髓磷脂瘤作为鉴别诊断,避免过度治疗。
{"title":"Rare huge bilateral adrenal myelolipoma confused with retroperitoneal liposarcoma","authors":"Kana Ito,&nbsp;Ryo Yamashita,&nbsp;Yuma Sakura,&nbsp;Hideo Shinsaka,&nbsp;Masafumi Nakamura,&nbsp;Masato Matsuzaki,&nbsp;Masashi Niwakawa,&nbsp;Tsubasa Hiraki","doi":"10.1002/iju5.12792","DOIUrl":"10.1002/iju5.12792","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Adrenal myelolipomas are uncommon benign adrenal tumors, which mostly occur unilaterally. We describe a rare case of giant bilateral adrenal myelolipoma mistaken for retroperitoneal liposarcoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A 49-year-old man developed fever, left flank pain, and a large mass in his left abdomen. Plain computed tomography showed a 23-cm mass with fat-containing components in the retroperitoneal cavity, suggestive of retroperitoneal liposarcoma. A similar 9-cm mass was observed in the right adrenal gland, suggesting adrenal metastasis. With a clinical diagnosis of retroperitoneal liposarcoma, we administered preoperative radiation therapy and performed a bilateral tumor resection. On postoperative day 9, a surgical site infection occurred, necessitating incisional drainage and the administration of intravenous antibiotics. The histopathological diagnosis was bilateral myelolipoma of the adrenal glands.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In cases of bilateral retroperitoneal tumors with a large fat component, adrenal myelolipoma should be considered in the differential diagnosis to avoid overtreatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 1","pages":"15-18"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11693103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cranial neuropathy following coronavirus disease 2019 vaccination in kidney transplant recipients 肾移植受者接种 2019 年冠状病毒疫苗后出现颅神经病变。
Q4 Medicine Pub Date : 2024-10-02 DOI: 10.1002/iju5.12761
Shota Fukae, Kazuaki Yamanaka, Soichi Matsumura, Ryo Tanaka, Shigeaki Nakazawa, Yoichi Kakuta, Norio Nonomura

Introduction

Understanding of adverse reactions to coronavirus disease 2019 vaccines remains limited.

Case presentation

Case 1: A 52-year-old woman, post-kidney transplantation, experienced sudden vision loss in her left eye after receiving a second dose of coronavirus disease 2019 vaccine. She was diagnosed with ischemic optic neuropathy.

Case 2: A 53-year-old woman, post-kidney transplantation, presented with worsening diplopia and left eye pain following the second dose of coronavirus disease 2019 vaccine. She was diagnosed with left abducens nerve palsy.

Conclusion

Vigilance is essential for recognizing the potential for delayed cranial neuropathy in immunocompromised individuals after coronavirus disease 2019 vaccination.

导言:对 2019 年冠状病毒病疫苗不良反应的了解仍然有限:病例 1:一名 52 岁的女性,肾移植术后,在接种第二剂 2019 年冠状病毒病疫苗后左眼视力突然下降。她被诊断为缺血性视神经病变。病例 2:一名 53 岁的女性,肾移植术后,接种第二剂 2019 年冠状病毒病疫苗后出现复视加重和左眼疼痛。她被诊断为左眼外展神经麻痹:要认识到接种冠状病毒病 2019 疫苗后免疫力低下的人可能会出现迟发性颅神经病,就必须保持警惕。
{"title":"Cranial neuropathy following coronavirus disease 2019 vaccination in kidney transplant recipients","authors":"Shota Fukae,&nbsp;Kazuaki Yamanaka,&nbsp;Soichi Matsumura,&nbsp;Ryo Tanaka,&nbsp;Shigeaki Nakazawa,&nbsp;Yoichi Kakuta,&nbsp;Norio Nonomura","doi":"10.1002/iju5.12761","DOIUrl":"10.1002/iju5.12761","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Understanding of adverse reactions to coronavirus disease 2019 vaccines remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>Case 1: A 52-year-old woman, post-kidney transplantation, experienced sudden vision loss in her left eye after receiving a second dose of coronavirus disease 2019 vaccine. She was diagnosed with ischemic optic neuropathy.</p>\u0000 \u0000 <p>Case 2: A 53-year-old woman, post-kidney transplantation, presented with worsening diplopia and left eye pain following the second dose of coronavirus disease 2019 vaccine. She was diagnosed with left abducens nerve palsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vigilance is essential for recognizing the potential for delayed cranial neuropathy in immunocompromised individuals after coronavirus disease 2019 vaccination.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 6","pages":"423-426"},"PeriodicalIF":0.0,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrence of mucinous prostate cancer in rectal wall due to needle-track seeding from previous transrectal prostate biopsy 直肠壁粘液性前列腺癌因之前经直肠前列腺活检的针道播种而复发。
Q4 Medicine Pub Date : 2024-10-01 DOI: 10.1002/iju5.12790
Tomoaki Hakariya, Kazune Teshima, Daiyu Aoki, Naoki Nishimura, Tetsuro Tominaga, Takashi Nonaka, Shunsuke Sato, Nozomi Ueki, Masahiro Nakashima, Ryoichi Imamura

Introduction

Needle-track seeding of prostate cancer into the rectal wall following transrectal prostate biopsy is exceedingly rare. We report a case of mucinous prostate cancer recurrence in the rectal wall due to biopsy needle seeding, discovered after robot-assisted radical prostatectomy.

Case presentation

A 67-year-old man underwent robot-assisted radical prostatectomy for mucinous prostate cancer (clinical stage T2cN0M0, Gleason score of 4 + 4, and initial prostate-specific antigen level of 8.8 ng/mL). Five years postoperatively, endoscopy revealed a rectal tumor, which was diagnosed as needle-track seeding from the previous transrectal prostate biopsy. Following resection of this rectal tumor, the patient's prostate-specific antigen level fell to <0.008 ng/mL. No signs of recurrence or metastasis were observed 3 months postoperatively.

Conclusion

While rare, transrectal prostate biopsies can pose a small risk of needle-track seeding into the rectal wall. Endorectal examination should be considered if biochemical recurrence of prostate cancer occurs following radical prostatectomy.

导言:经直肠前列腺活检后,前列腺癌针迹播种到直肠壁的情况极为罕见。我们报告了一例在机器人辅助前列腺癌根治术后发现的因活检针播种导致直肠壁粘液性前列腺癌复发的病例:一名 67 岁的男性因患粘液性前列腺癌(临床分期 T2cN0M0,格里森评分 4 + 4,初始前列腺特异性抗原水平为 8.8 纳克/毫升)接受了机器人辅助前列腺癌根治术。术后五年,内镜检查发现直肠肿瘤,诊断为之前经直肠前列腺活检的针道播散。切除直肠肿瘤后,患者的前列腺特异性抗原水平降至结论水平:经直肠前列腺活检虽然罕见,但可能会造成针迹播散到直肠壁的小风险。如果前列腺癌根治术后出现生化复发,应考虑进行直肠内检查。
{"title":"Recurrence of mucinous prostate cancer in rectal wall due to needle-track seeding from previous transrectal prostate biopsy","authors":"Tomoaki Hakariya,&nbsp;Kazune Teshima,&nbsp;Daiyu Aoki,&nbsp;Naoki Nishimura,&nbsp;Tetsuro Tominaga,&nbsp;Takashi Nonaka,&nbsp;Shunsuke Sato,&nbsp;Nozomi Ueki,&nbsp;Masahiro Nakashima,&nbsp;Ryoichi Imamura","doi":"10.1002/iju5.12790","DOIUrl":"10.1002/iju5.12790","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Needle-track seeding of prostate cancer into the rectal wall following transrectal prostate biopsy is exceedingly rare. We report a case of mucinous prostate cancer recurrence in the rectal wall due to biopsy needle seeding, discovered after robot-assisted radical prostatectomy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case presentation</h3>\u0000 \u0000 <p>A 67-year-old man underwent robot-assisted radical prostatectomy for mucinous prostate cancer (clinical stage T2cN0M0, Gleason score of 4 + 4, and initial prostate-specific antigen level of 8.8 ng/mL). Five years postoperatively, endoscopy revealed a rectal tumor, which was diagnosed as needle-track seeding from the previous transrectal prostate biopsy. Following resection of this rectal tumor, the patient's prostate-specific antigen level fell to &lt;0.008 ng/mL. No signs of recurrence or metastasis were observed 3 months postoperatively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>While rare, transrectal prostate biopsies can pose a small risk of needle-track seeding into the rectal wall. Endorectal examination should be considered if biochemical recurrence of prostate cancer occurs following radical prostatectomy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 6","pages":"499-502"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
IJU Case Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1